Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.
Researchers from the Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish National Research Council (CSIC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback